protagonist-inc.com 的前十大競爭對手

annexonbio.com

Russ, GBS survivor and patient advocate COMMITTED TO HELPING PEOPLE WITH GBS LIVE THEIR BEST LIVES Annexon is working to deliver game-changing therapies for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. This includes our flagship investigational candidate for GBS, and a next wave of programs targeting Huntington’s Disease […]

adaptimmune.com

After Adaptimmune has affinity-enhanced a TCR, the company can deliver it to patients through a robust and commercialized manufacturing process.

metagentx.com

腸内細菌研究に基づいた医療・創薬を推進

elevartx.com

Lirafugratinib is a highly selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors1,2

dianthustx.com

Dianthus Therapeutics is harnessing the power of selectivity to advance next-generation complement therapies.

bioversys.com

Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 - an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars - a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and…

amgenpipeline.com

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible.

pharmaceutical-technology.com

Stay updated with the latest pharmaceutical industry news, trends, and insights. Explore in-depth analysis and expert reports. Visit us today!